de Jong M, et al. - The impacts of pioglitazone treatment on the secondary prevention of cardiovascular diseases (CVD) were investigated via a systematic review and meta-analysis. Findings demonstrated that in patients with clinical manifest vascular disease, treatment with pioglitazone reduced the risk of recurrent major adverse cardiovascular events (MACE), stroke, or myocardial infarction (MI). Furthermore, evidence reported no reduction in the risk of all-cause mortality as a consequence of pioglitazone treatment, rather an increase in the heart failure (HF) risk was noted in those treated with pioglitazone.